跳至主要内容
临床试验/NCT03998293
NCT03998293撤回4 期

Direct Measurement of Proinsulin Clearance in Humans

Mayo Clinic1 个研究点 分布在 1 个国家开始时间: 2022年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
发起方
Mayo Clinic
试验地点
1
主要终点
Proinsulin Distribution

研究概览

简要总结

Researchers are trying to determine how quickly proinsulin is cleared from the circulation.

详细描述

proinsulin clearance is necessary to determine the rate of secretion into the circulation

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
25 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Weight-stable, non-diabetic subjects from Biobank participants at Mayo Clinic, Rochester

排除标准

  • Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • HbA1c ≥ 6.5%
  • Use of glucose-lowering agents.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Hormone replacement therapy >0.625 mg premarin daily

研究组 & 干预措施

proinsulin clearance

Other

all participants will be studied once where somatostatin will be used to block endogenous insulin secretion

干预措施: Somatostatin (Drug)

结局指标

主要结局

Proinsulin Distribution

时间窗: through study completion, each study will take an average of 8 hours

The volume of distribution of proinsulin in a given individual

Proinsulin Clearance

时间窗: through study completion, each study will take an average of 8 hours

The half-life of proinsulin in a given individual

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Adrian Vella

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验